REGN
Regeneron Pharmaceuticals, Inc.
$662.88
-13.35 (-1.97%)
At close · Jul 8
Market Cap
$70.03B
Shares
104,839,032
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$14.34B
+1%
FY2025
Net Income
$4.5B
+2.1%
FY2025
Gross Margin
93.86%
-1.5pp
FY2019
Operating Margin
24.95%
-3.2pp
FY2025
Diluted EPS
$41.48
+8.2%
FY2025
Operating Cash Flow
$4.98B
+12.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $14.92B | $14.34B | $14.2B | $13.12B | $12.17B | $16.07B | $8.5B | $6.56B | $5.15B | $5.87B | $4.86B | $4.1B | $2.82B | $2.1B | $1.38B | $445.82M | $459.07M | $379.27M | $238.46M | |
| — | — | — | — | — | — | — | $402.8M | $237.5M | $202.51M | $194.62M | $241.7M | $129.03M | $118.05M | $83.93M | $4.22M | $2.09M | $1.69M | $923K | |
| — | — | — | — | — | — | — | $6.15B | $4.91B | $5.67B | $4.67B | $3.86B | $2.69B | $1.99B | $1.29B | $441.61M | $456.98M | $377.58M | $237.53M | |
| — | — | — | — | — | — | — | 93.86% | 95.38% | 96.55% | 96% | 94.11% | 95.42% | 94.39% | 93.91% | 99.05% | 99.54% | 99.56% | 99.61% | |
| $6.07B | $5.85B | $5.13B | $4.44B | $3.59B | $2.86B | $2.65B | $2.45B | $1.47B | $2.08B | $2.05B | $1.62B | $1.27B | $859.95M | $625.55M | $529.51M | $489.25M | $398.76M | $274.9M | |
| $2.71B | $2.7B | $2.95B | $2.63B | $2.12B | $1.82B | $1.35B | $1.34B | $1.13B | $1.32B | $1.18B | $838.53M | $519.27M | $346.39M | $210.76M | $117.26M | $65.2M | $52.92M | $48.88M | |
| — | $178.8M | $128.9M | $92.2M | $37.6M | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $543.7M | $482.9M | $421M | $341.4M | $286.2M | $235.9M | $210.3M | $148.2M | $145.5M | $104.7M | $74.91M | $52.69M | $41.2M | $36.94M | $31.08M | $19.69M | $14.2M | $11.29M | |
| $11.29B | $10.77B | $10.21B | $9.07B | $7.43B | $7.12B | $4.92B | $4.35B | $2.61B | $3.79B | $3.53B | $2.85B | $2B | $1.36B | $920.76M | $650.98M | $556.55M | $453.37M | $324.71M | |
| $3.63B | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B | $2.08B | $1.33B | $1.25B | $823.92M | $743.05M | $457.71M | -$205.16M | -$97.47M | -$74.1M | -$86.25M | |
| — | 24.95% | 28.1% | 30.85% | 38.93% | 55.67% | 42.09% | 33.7% | 49.25% | 35.41% | 27.38% | 30.51% | 29.22% | 35.3% | 33.2% | -46.02% | -21.23% | -19.54% | -36.17% | |
| — | $4.12B | $4.47B | $4.47B | $5.08B | $9.23B | $3.81B | $2.42B | $2.68B | $2.23B | $1.44B | $1.33B | $876.61M | $784.25M | $494.65M | -$174.08M | -$77.79M | -$59.9M | -$74.96M | |
| $48M | $43.8M | $55.2M | $73M | $59.4M | $57.3M | $56.9M | $30.2M | $28.2M | $25.1M | $7.2M | $14.24M | $37.37M | $46.44M | $45.3M | $21.28M | $9.12M | $2.34M | $7.75M | |
| $1.53B | $1.65B | $789.2M | $152.2M | $119.9M | $379M | $233.8M | $219.3M | $19.1M | -$1.1M | -$900K | -$26.82M | -$62.68M | -$46.67M | -$43.29M | -$17.73M | -$7M | $2.15M | $9.47M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$293K | $56K | -$1.31M | |
| $5.16B | $5.23B | $4.78B | $4.2B | $4.86B | $9.33B | $3.81B | $2.43B | $2.55B | $2.08B | $1.33B | $1.23B | $761.24M | $696.38M | $414.42M | -$222.89M | -$104.47M | -$71.95M | -$76.78M | |
| $733.5M | $725.8M | $367.3M | $245.7M | $520.4M | $1.25B | $297.2M | $313.3M | $109.1M | $880M | $434.3M | $589.04M | $423.11M | $282.64M | -$335.85M | -$1.13M | $0 | -$4.12M | $2.35M | |
| $4.42B | $4.5B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.2B | $895.5M | $636.06M | $338.13M | $413.74M | $750.27M | -$221.76M | -$104.47M | -$67.83M | -$79.13M | |
| — | 31.41% | 31.07% | 30.14% | 35.64% | 50.25% | 41.35% | 32.26% | 47.5% | 20.41% | 18.42% | 15.5% | 11.99% | 19.66% | 54.43% | -49.74% | -22.76% | -17.88% | -33.18% | |
| $4.41B | $4.59B | $4.49B | $4.11B | $4.13B | $8.02B | $3.52B | $2.15B | $2.44B | $1.21B | $874.1M | $592.38M | $391.57M | $413.72M | $750.97M | -$221.13M | -$108M | — | — | |
| USD/shares | — | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $22.65 | $11.27 | $8.55 | $6.17 | $3.36 | $4.23 | $7.92 | -$2.45 | -$1.26 | — | — |
| USD/shares | — | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $2.98 | $3.72 | $6.75 | -$2.45 | -$1.26 | — | — |
| shares | — | 104.6M | 107.9M | 106.7M | 107.1M | 105.7M | 107.6M | 109.2M | 107.9M | 106.3M | 104.7M | 103.06M | 100.61M | 97.92M | 94.69M | 90.61M | 82.93M | — | — |
| shares | — | 108.6M | 115.1M | 113.7M | 113.5M | 112.2M | 115.1M | 114.6M | 114.8M | 115.9M | 116.3M | 115.23M | 113.41M | 111.29M | 115.38M | 90.61M | 82.93M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $18.13B in buybacks, $370.3M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
16.31×
Biotechnology median 7.68×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| United States | $6,893,700,000 | $12,117,200,000 | $5,567,600,000 | $4,834,400,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue | $7,331,200,000 | $6,057,800,000 | $5,503,100,000 | $4,914,100,000 | $3,673,300,000 | $1,186,100,000 | — | — |
| Product | $6,309,100,000 | $7,629,200,000 | $7,078,000,000 | $6,893,700,000 | $12,117,200,000 | $5,567,600,000 | $4,834,400,000 | $4,106,200,000 |
| LIBTAYO Net Product Sales | $1,452,200,000 | $1,216,800,000 | $863,100,000 | $447,500,000 | $306,300,000 | — | — | — |
| Product And Service Other | $702,600,000 | $515,000,000 | $536,100,000 | $365,100,000 | $281,200,000 | $557,000,000 | $174,000,000 | — |
| Other Products | $10,100,000 | $0 | $0 | — | — | — | — | — |
| Sanofi Collaboration Revenue | — | — | — | $2,855,700,000 | $1,902,200,000 | $1,186,400,000 | — | — |
Key facts
CIK
872589
CUSIP
75886F107
13F (30d)
113 filings
67 filers
Visit website
Investor relations